Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says

MT Newswires Live09-26

Acadia Pharmaceuticals' (ACAD) favorable risk-reward remains intact despite remlifanserin narrowly missing statistical significance in a phase 2 trial in Alzheimer's disease psychosis, with the commercial base business supporting valuation, Deutsche Bank said in a Friday note.

The 60 milligram dose narrowly missed statistical significance, but Deutsche Bank said the data showed a dose response, separation from placebo beginning at Week 2 and widening through Week 6, and a clean safety profile.

The bank said remlifanserin has a pimavanserin-like profile that could be attractive commercially, supported by long-dated intellectual property.

Deutsche Bank also cited improving commercial prospects for Nuplazid and Daybue.

The investment bank reduced its probability of success for remlifanserin in Alzheimer's disease psychosis and Lewy body dementia psychosis.

Deutsche Bank maintained its Buy rating and lowered its price target to $31 from $38.

Shares of Acadia were 5.7% lower in Friday afternoon trading.

Price: 20.90, Change: -1.28, Percent Change: -5.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2670542610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-26 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2670542610","market":"hk","top_or_hot":-1,"title":"Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says","media":"MT Newswires Live","content":"<html><body><p> Acadia Pharmaceuticals' (ACAD) favorable risk-reward remains intact despite remlifanserin narrowly missing statistical significance in a phase 2 trial in Alzheimer's disease psychosis, with the commercial base business supporting valuation, Deutsche Bank said in a Friday note.</p><p>The 60 milligram dose narrowly missed statistical significance, but Deutsche Bank said the data showed a dose response, separation from placebo beginning at Week 2 and widening through Week 6, and a clean safety profile.</p><p>The bank said remlifanserin has a pimavanserin-like profile that could be attractive commercially, supported by long-dated intellectual property.</p><p>Deutsche Bank also cited improving commercial prospects for Nuplazid and Daybue.</p><p>The investment bank reduced its probability of success for remlifanserin in Alzheimer's disease psychosis and Lewy body dementia psychosis.</p><p>Deutsche Bank maintained its Buy rating and lowered its price target to $31 from $38.</p><p>Shares of Acadia were 5.7% lower in Friday afternoon trading.</p><p>Price: 20.90, Change: -1.28, Percent Change: -5.77</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-26 00:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Acadia Pharmaceuticals' (ACAD) favorable risk-reward remains intact despite remlifanserin narrowly missing statistical significance in a phase 2 trial in Alzheimer's disease psychosis, with the commercial base business supporting valuation, Deutsche Bank said in a Friday note.</p><p>The 60 milligram dose narrowly missed statistical significance, but Deutsche Bank said the data showed a dose response, separation from placebo beginning at Week 2 and widening through Week 6, and a clean safety profile.</p><p>The bank said remlifanserin has a pimavanserin-like profile that could be attractive commercially, supported by long-dated intellectual property.</p><p>Deutsche Bank also cited improving commercial prospects for Nuplazid and Daybue.</p><p>The investment bank reduced its probability of success for remlifanserin in Alzheimer's disease psychosis and Lewy body dementia psychosis.</p><p>Deutsche Bank maintained its Buy rating and lowered its price target to $31 from $38.</p><p>Shares of Acadia were 5.7% lower in Friday afternoon trading.</p><p>Price: 20.90, Change: -1.28, Percent Change: -5.77</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKR","symbol_name":"阿卡迪亚房地产信托","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2670542610","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2670542610","pubTimestamp":1790354048,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Acadia Pharmaceuticals'  favorable risk-reward remains intact despite remlifanserin narrowly missing statistical significance in a phase 2 trial in Alzheimer's disease psychosis, with the commercial base business supporting valuation, Deutsche Bank said in a Friday note.The 60 milligram dose narrowly missed statistical significance, but Deutsche Bank said the data showed a dose response, separation from placebo beginning at Week 2 and widening through Week 6, and a clean safety profile.The bank said remlifanserin has a pimavanserin-like profile that could be attractive commercially, supported by long-dated intellectual property.Deutsche Bank also cited improving commercial prospects for Nuplazid and Daybue.The investment bank reduced its probability of success for remlifanserin in Alzheimer's disease psychosis and Lewy body dementia psychosis.Deutsche Bank maintained its Buy rating and lowered its price target to $31 from $38.Shares of Acadia were 5.7% lower in Friday afternoon trading","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKR":"阿卡迪亚房地产信托","DB":"德意志银行","BK4118":"综合性资本市场","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4231":"零售房地产信托","ACAD":"阿卡迪亚","BK4566":"资本集团","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4588":"碎股","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4080":"零售业房地产投资信托","BK4585":"ETF&股票定投概念","BK4552":"Archegos爆仓风波概念","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4139":"生物科技"},"translate_title":"德意志银行表示，瑞姆利凡色林数据公布后，阿卡迪亚制药公司的风险回报有利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKR":1.5,"ACAD":1,"DB":1.5},"content_text":"Acadia Pharmaceuticals' (ACAD) favorable risk-reward remains intact despite remlifanserin narrowly missing statistical significance in a phase 2 trial in Alzheimer's disease psychosis, with the commercial base business supporting valuation, Deutsche Bank said in a Friday note.The 60 milligram dose narrowly missed statistical significance, but Deutsche Bank said the data showed a dose response, separation from placebo beginning at Week 2 and widening through Week 6, and a clean safety profile.The bank said remlifanserin has a pimavanserin-like profile that could be attractive commercially, supported by long-dated intellectual property.Deutsche Bank also cited improving commercial prospects for Nuplazid and Daybue.The investment bank reduced its probability of success for remlifanserin in Alzheimer's disease psychosis and Lewy body dementia psychosis.Deutsche Bank maintained its Buy rating and lowered its price target to $31 from $38.Shares of Acadia were 5.7% lower in Friday afternoon trading.Price: 20.90, Change: -1.28, Percent Change: -5.77","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2670542610","isCrawlerRequest":true}